Search
All Posts
We Analysed 196 Regulatory Affairs Career Changers — Here's What Actually Predicts Success
A regulatory affairs career change success analysis of 196 course registrants found that only 16 people (8.2%) transitioned into a regulatory affairs role, and their profiles differ sharply from the wider group. This affects anyone considering a move into regulatory affairs — scientists, pharmacists, graduates and existing regulatory professionals. The data, collected between September 2024 and May 2026, shows that active job searching, existing regulatory or science experien
Aug 1810 min read
Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
Aug 1413 min read
UK Launches New MHRA Regulatory Sandbox for AI-Enabled Medical Devices: What London Region I Means for Regulatory Affairs
The MHRA AI regulatory sandbox for medical devices, known as London Region I, allows up to 10 AI-enabled medical device manufacturers to deploy their technologies in real NHS clinical settings under regulatory oversight while generating real-world safety and effectiveness evidence. This affects AI medical device manufacturers, NHS providers across London, and UK regulatory affairs professionals working in medical devices. It applies from the Expression of Interest stage opene
Aug 1413 min read
eCTD 4.0 Explained: FDA, EMA and Japan Deadlines, Key Changes and What It Means for Regulatory Affairs Careers
**eCTD 4.0** is the next-generation global standard for electronic pharmaceutical regulatory submissions, replacing the document-centric **eCTD 3.2.2** format used since 2008. It affects regulatory affairs professionals, publishing specialists and every company submitting dossiers to the **FDA**, **EMA**, **PMDA** and other health authorities. The **FDA** has accepted eCTD 4.0 for new applications since **16 September 2024**; **Japan** targets a mandate by **April 2026**; and
Aug 1212 min read
The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers
The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment
Aug 1212 min read
Regulatory Affairs Professional Stuck at the Same Level? Here's Why Most Regulatory Affairs Training Isn't Getting You Promoted
Regulatory affairs career progression stalls for most professionals not because they lack knowledge, but because their training and CV never move beyond execution-level tasks. Associates and specialists who have completed generic CPD courses, webinars or self-study modules often still cannot demonstrate ownership of a Marketing Authorisation Application (MAA) section, a variation classification decision, or a cross-region regulatory strategy — the exact evidence hiring panels
Aug 1011 min read